Treatment of Feline Injection-Site Sarcomas with Iridium Implants

A retrospective study looked at the effectiveness of using iridium implants in addition to surgery in cats with feline injection-site sarcomas (FISSs). Twenty-two cats with FISS were treated with surgery and brachytherapy delivered by postoperative iridium-192 implants. Radiation doses ranged from 4000-6000 cGy with most doses delivered over 7 days.

Related: Get our Surgical Insights Guide

The median number of surgeries prior to brachytherapy was one (range 1-4). The median time to progression for all cats was 619 days and disease-specific survival time for all cats was 1242 days. The 1 and 2 year tumor-free rates in these cats were 63.6% and 40.9%, respectively. The local failure rate was 54.5% and the distant failure rate was 13.6% due to lung metastasis. There was a significant difference in time to progression of cats that had a single surgery performed prior to brachytherapy and those that had multiple surgeries.

Read more by clicking on the link below:

Treatment of feline injection-site sarcoma with surgery and iridium-192 brachytherapy: retrospective evaluation of 22 cats.

Previous
Previous

Efficacy of Treatment for Feline Lymphoma

Next
Next

Postmortem Evaluation of Renal Tubular Vacuolization in Critically Ill Dogs